亚胺培南西司他丁钠使用管理监测及合理性分析

Antimicrobial stewardship monitoring and rationality analysis of imipenem and cilastatin sodium

目的:加强医院亚胺培南西司他丁钠管理及临床合理使用。方法:采用回顾性研究方法,分析某院2017年6月使用亚胺培南西司他丁钠的住院患者121例,使用Excel 2013软件对患者资料、药物使用情况等数据进行统计分析,参照抗菌药物临床应用指导原则(2015)及相关指南进行合理性评价。结果:在使用亚胺培南西司他丁钠的121例病例中,用药前微生物送检率为76. 86%,用药不合理病例为13例。结论:某院住院患者亚胺培南西司他丁钠的管理和临床应用仍存在不合理情况,药师应及时向临床反馈点评结果,以促进碳青霉烯类抗菌药物规范使用。

Objective: To strengthen the stewardship of imipenem-cilastatin sodium and improve its rational use in hospitals. Methods: A retrospective analysis was conducted on 121 cases of patients who used imipenemcilastatin sodium in June 2017. Excel 2007 software was used for statistical analysis of patient data,drug use and other data,and rationality evaluation was conducted with reference to the 'Guiding Principles of Clinical Use of Antibiotics (2015) 'and other related guidelines. Results: In the 121 cases of imipenem-cilastatin sodium use,the microbial samples submission rate before drug treatment was 76. 86% and 13 cases were irrational use. Conclusion:There are still some irrational cases in the clinical use of imipenem-cilastatin sodium. Pharmacists should timely feedback the results to the doctors and promote the rational use of carbapenems.